Equity Research
Fundamental analysis, company comparisons, balance-sheet reviews, and equity valuation.
Range Resources Stock Analysis: Buy or Sell? Valuation, Cash Flow & Gas Risk
Range Resources (RRC) is rated Hold as strong cash generation and a modest balance sheet offset a valuation that already reflects the upside. Its cash flows are solid, but heavy natural-gas exposure keeps the equity tied to commodity pricing.
NexGen Energy Stock Analysis: Buy or Sell? Valuation, Cash Burn & Liquidity
NexGen Energy Ltd. (NXE) is rated Sell as the company is still funding growth ahead of durable cash generation. Despite a recent EBITDA rebound, negative operating cash flow and levered free cash flow keep the investment case dependent on financing and execution.
Nabors Industries Stock Analysis: Buy or Sell? Valuation, FCF & Customer Risk
Nabors Industries Ltd. (NBR) is rated Hold as its balance sheet and 9.6% FCF yield support the stock, but revenue has not reaccelerated enough to justify a more aggressive stance. Heavy customer concentration, led by Saudi Aramco, remains the main reason for caution.
Extra Space Storage Stock Analysis: Buy or Sell? Valuation, Leverage & Cash Flow
Extra Space Storage (EXR) is rated Hold as its strong self-storage moat is offset by a premium valuation and rising leverage. TTM free cash flow yield is 4.7%, while net debt/EBITDA sits at 5.9x, leaving less room for execution misses.
Sphere Entertainment Stock Analysis: Buy or Sell? Valuation, Debt & Cash Flow
Sphere Entertainment Co. (SPHR) is rated Hold as real free cash flow offsets a still-negative operating margin and a rich valuation. Debt load and the MSG Networks term loan remain the key balance-sheet risks.
Flowserve Stock Analysis: Buy or Sell? Valuation, Debt, Free Cash Flow
Flowserve Corporation (FLS) is rated Hold as its installed-base service network supports cash generation, but revenue remains flat to down. The stock looks fairly valued, while 2.2x net debt/EBITDA keeps leverage and backlog conversion on watch.
Altimmune Stock Analysis: Buy or Sell? Valuation, Cash Burn & Phase 3
Altimmune (ALT) is rated Sell as the stock already prices in Phase 3 success while the business remains pre-revenue. Despite $326.3 million in cash and a strong current ratio, negative free cash flow and heavy development spending keep the risk profile elevated.
StubHub Stock Analysis: Buy or Sell? Valuation, FCF & Margins
StubHub Holdings Inc. (STUB) is rated Hold as strong cash generation and a low net debt load are offset by deeply negative EBITDA margins. The marketplace still posts excellent gross margins, but profitability has not yet proven durable enough for a higher rating.
Voya Financial Stock Analysis: Buy or Sell? Valuation & Cash Flow
Voya Financial, Inc. (VOYA) is rated Hold as strong free cash flow supports the shares, but softer earnings momentum keeps the setup from looking outright cheap. Valuation is fair, and the key upside trigger is a move in operating margin toward the low double digits.
Ryder Stock Analysis: Buy or Sell? Leverage, Valuation & FCF
Ryder System, Inc. (R) is rated Hold as strong free cash flow is offset by elevated leverage and weak liquidity. The stock looks fairly priced on a 13.9x forward P/E, but 2.96x net debt/EBITDA and a 0.65 current ratio limit upside if freight softens.
Most Popular Research
Subscribe
Get future lf0 research notes by email.
Equity research, scorecards, weekly performance updates, and SEC filing-change summaries.